Your browser doesn't support javascript.
loading
Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs.
Fershtat, Leonid L; Makhova, Nina N.
Afiliação
  • Fershtat LL; N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp. 47, Moscow, 119991, Russian Federation.
  • Makhova NN; N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp. 47, Moscow, 119991, Russian Federation.
ChemMedChem ; 12(9): 622-638, 2017 05 09.
Article em En | MEDLINE | ID: mdl-28371340
ABSTRACT
The molecular hybridization of different compounds with known pharmacological activity is a particularly prominent approach for the design of potential drugs with improved pharmacokinetic profiles. Much attention over the last decade has been focused on the synthesis of hybrid structures with a nitric oxide (NO)-donor framework, as NO is a ubiquitous and crucial regulator of cellular metabolism, affecting various physiological and pathophysiological processes. 1,2,5-Oxadiazole 2-oxides (furoxans), which are capable of exogenous NO release in the presence of thiol cofactors, are an important class of prospective NO donors. As such, a wide range of hybrid compounds that combine a furoxan ring with various pharmacologically active structures have been created. This review focuses on recent results in the synthesis and pharmacological activity of furoxan-based hybrids. Special attention is given to chemo- and regioselective methods used in the preparation of these hybrid structures, and the role of synergistic effects on their pharmacological activity, associated with the furoxan fragment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pró-Fármacos / Doadores de Óxido Nítrico Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pró-Fármacos / Doadores de Óxido Nítrico Idioma: En Ano de publicação: 2017 Tipo de documento: Article